Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
GSK Starts Trial Of HGS Diabetes Drug
by Ann M. Thayer
February 23, 2009
| A version of this story appeared in
Volume 87, Issue 8
GlaxoSmithKline's start of Phase III clinical trials of Syncria, a glucagon-like peptide 1 agonist for treating type 2 diabetes, has triggered a $9 million payment to Human Genome Sciences (HGS). Syncria is an injectable, longer acting form of human GLP-1 peptide, which helps maintain normal blood-sugar levels and control appetite. The studies are aimed at proving the drug's efficacy and cardiovascular safety and will take two or three years to complete. HGS licensed Syncria to GSK in 2004 and could reap another $159 million in milestone fees, as well as royalties, if the drug is commercialized.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter